Issue 26, 2021

Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides

Abstract

SARS-CoV-2 Spike protein RBD interacts with the hACE2 receptor to initiate cell entry and infection. We set out to develop lactam-based i,i + 4 stapled hACE2 peptides targeting SARS-CoV-2. In vitro screening demonstrates the inhibition of the Spike protein RBD-hACE2 complex formation by the hACE221-55A36K-F40E stapled peptide (IC50: 3.6 μM, Kd: 2.1 μM), suggesting that hACE2 peptidomimetics could form the basis for the development of anti-COVID-19 therapeutics.

Graphical abstract: Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides

Supplementary files

Article information

Article type
Communication
Submitted
28 Dec 2020
Accepted
16 Feb 2021
First published
02 Mar 2021
This article is Open Access
Creative Commons BY license

Chem. Commun., 2021,57, 3283-3286

Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides

M. N. Maas, J. C. J. Hintzen, P. M. G. Löffler and J. Mecinović, Chem. Commun., 2021, 57, 3283 DOI: 10.1039/D0CC08387A

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements